Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
2.
Eur J Echocardiogr ; 10(4): 549-55, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19211568

RESUMEN

AIMS: Relationship between obesity and cardiovascular (CV) disease depends not only on the amount of body fat, but also on its distribution. For example, individuals with increased fat accumulation in the abdominal region have atherogenic lipid profiles and are at increased CV risk. The loss of elasticity in medium and large arteries is an early manifestation of atherosclerosis. The aim of this study was to evaluate whether echocardiographic epicardial adipose tissue, an index of cardiac adiposity, is related to carotid stiffness and carotid intima-media thickness (IMT), indexes of subclinical atherosclerosis, better than waist circumference in hypertensive patients. METHODS AND RESULTS: We studied 459 patients with Grade I and II essential hypertension who were referred to our outpatient clinic over a period from May 2007 to March 2008. The population was first sorted by waist circumference and then by epicardial fat < or = 7 or >7 mm. We measured epicardial fat thickness, waist circumference, carotid artery stiffness, and carotid IMT in all patients. Patients divided according to waist circumference showed no statistical differences in carotid artery stiffness between the two groups. Subjects with epicardial fat >7 mm were older, had higher systolic, diastolic, and pulse pressure, increased left ventricular mass index, carotid IMT, diastolic parameters, and stiffness parameters compared with those with epicardial fat < or = 7 mm (P < 0.001). A positive correlation was found between epicardial fat and age, pulse pressure, stiffness parameters, carotid IMT, systolic blood pressure, and duration of hypertension, and a negative correlation was found with diastolic parameters. Age, carotid IMT, and stiffness parameters were independently related to epicardial fat. CONCLUSION: Our findings indicate that epicardial fat reflects carotid artery stiffness in hypertension-induced organ damage.


Asunto(s)
Tejido Adiposo/diagnóstico por imagen , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Hipertensión/diagnóstico por imagen , Obesidad/diagnóstico por imagen , Pericardio/diagnóstico por imagen , Tejido Adiposo/patología , Adulto , Anciano , Anciano de 80 o más Años , Presión Sanguínea , Arterias Carótidas/diagnóstico por imagen , Arterias Carótidas/fisiopatología , Enfermedades de las Arterias Carótidas/etiología , Enfermedades de las Arterias Carótidas/fisiopatología , Ecocardiografía , Ecocardiografía Doppler de Pulso , Femenino , Humanos , Hipertensión/etiología , Hipertensión/fisiopatología , Grasa Intraabdominal/diagnóstico por imagen , Modelos Lineales , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Pericardio/patología , Factores de Riesgo , Circunferencia de la Cintura , Adulto Joven
3.
Drugs Aging ; 19(10): 723-32, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12390049

RESUMEN

Newer classes of antihypertensive agents, such as angiotensin II receptor antagonists, may offer benefits to patients in addition to their ability to lower blood pressure. It is accepted that chronic hypertension contributes to the development of cerebrovascular and cardiovascular disease, and several studies have demonstrated a link between hypertension and reduced cognitive function, especially in patients not receiving antihypertensive medication. In an initial clinical trial, the angiotensin II receptor antagonist losartan was shown to improve cognitive function in patients with hypertension, including in those who were elderly (up to 73 years of age). This effect cannot be explained by a reduction in blood pressure alone and is likely to involve interactions with the diverse biological actions of the renin-angiotensin system. Improving or maintaining cognitive function in patients with hypertension may translate into economic benefits beyond those expected due to blood pressure control, and would result in considerable quality-of-life benefits for the aging population.


Asunto(s)
Angiotensina II/metabolismo , Antagonistas de Receptores de Angiotensina , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Trastornos del Conocimiento/tratamiento farmacológico , Losartán/uso terapéutico , Anciano , Anciano de 80 o más Años , Envejecimiento/fisiología , Inhibidores de la Enzima Convertidora de Angiotensina/farmacocinética , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Animales , Antihipertensivos/farmacocinética , Antihipertensivos/farmacología , Ensayos Clínicos como Asunto , Trastornos del Conocimiento/economía , Trastornos del Conocimiento/etiología , Humanos , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Hipertensión/economía , Losartán/farmacocinética , Losartán/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...